Table 1 Patient demographic and baseline characteristics
Characteristic | N = 39 |
|---|---|
Age (years), median (range) | 48 (20–64) |
Sex | |
 Male | 33 (84.6) |
 Female | 6 (15.4) |
ECOG performance status | |
 0 | 19 (48.7) |
 1 | 20 (51.3) |
Histology | |
 Non-keratinizing | 32 (82.1) |
  Undifferentiated (type III) | 0 |
  Differentiated (type II) | 0 |
 Keratinizing squamous cell carcinoma | 7 (17.9) |
 Unclassified |  |
Disease stage | |
 Nasopharynx recurrent disease only | 2 (5.1) |
 Cervical LN recurrent disease only | 2 (5.1) |
 Nasopharynx and cervical LN recurrent disease | 1 (3.6) |
 Nasopharynx recurrent and metastatic disease | 1 (3.6) |
 Cervical LN recurrent and metastatic disease | 6 (15.4) |
 Metastatic disease only | 27 (69.2) |
Metastasis type | |
 Oligometastasis | 20 (51.3) |
 Polymetastases | 19 (48.7) |
Metastatic site | |
 Liver | 24 (61.5) |
 Lung | 18 (46.2) |
 Bone | 17 (43.6) |
 Lymph node | 32 (82.1) |
EBV DNA | |
  ≥ 1000 IU/mL | 16 (41.0) |
  < 1000 IU/mL | 23 (59.0) |
Baseline LDH | |
  ≥ 1 × ULN | 13 (33.3) |
  < 1× ULN | 26 (66.7) |
Prior lines of systemic treatmenta | |
 2L | 29 (74.4) |
 3L | 7 (17.9) |
 4L +  | 3 (7.7) |
Previous systemic therapy | |
 Cisplatin | 36 (92.3) |
 Carboplatin | 3 (7.7) |
 Gemcitabine | 31 (79.5) |
 Fluorouracil | 14 (35.9) |
 Docetaxel | 24 (61.5) |
 Paclitaxel | 17 (43.6) |
 Capecitabine | 16 (41.0) |
 S-1 | 22 (56.4) |
 Anti-PD-1 immunotherapy | 19 (48.7) |
 Anti-EGFR antibody | 15 (38.5) |
Previous radiotherapy | 35 (89.7) |